https://www.selleckchem.com/pr....oducts/Gefitinib.htm
The odds of having a concomitant procedure was 2.7 times higher in patients with an IMr TAR (OR 2.7, CI 1.7-4.4; .0001). There were similar improvements in patient-reported outcome scores at 1 year and final follow-up (all .05). The 5-year implant survivorship was 98.6% for IMr vs 97.5% for EMr at final follow-up. The IMr and EMr TAR components had comparable postoperative alignment, patient-reported outcome scores, and complications. The 5-year implant survivorship was similar between the IMr and EMr groups. Level III, retr
Like
Comment
Share
